IP Library › Granted Patent US 11,001,629
Granted Patent B2
US 11,001,629 · App. 16/066,688 · Granted May 11, 2021

Variable regions for NKp46 binding proteins

Inventors: Laurent Gauthier (Marseilles, FR); Nadia Anceriz (Marseilles, FR); Ariane Morel (Marseilles, FR); Benjamin Rossi (Marseilles, FR)
Assignee: INNATE PHARMA
C07K16/2803C07K16/2809C07K16/2887C07K16/468C07K2317/24C07K2317/31C07K2317/33C07K2317/34C07K2317/526C07K2317/622C07K2317/732C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,001,629
App. No.
16/066,688
Granted
May 11, 2021
Kind
B2
Abstract

NKp-46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

Claims (12)

1. A protein or polypeptide comprising an antigen binding domain that binds a human NKp46 polypeptide, wherein the domain comprises a heavy chain variable region (VH) and a light chain variable region (VL) combination selected from the group consisting of:

(a) a VH comprising an amino acid sequence of SEQ ID NOS: 199 or 200 (NKp46-1 H1 or H3 variable domain), and a VL comprising an amino acid sequence of the amino acid sequence of SEQ ID NO: 201 (NKp46-1 L1 variable domain);

(b) a VH comprising an amino acid sequence of SEQ ID NOS: 202, 203 or 204 (NKp46-2 H1, H2 or H3 variable domain), and a VL comprising an amino acid sequence of SEQ ID NO: 205 (NKp46-2 L1 variable domain);

(c) a VH comprising an amino acid sequence of SEQ ID NOS: 206, 207 or 208 (NKp46-3 H1, H3 or H4 variable domain), and a VL comprising an amino acid sequence of SEQ ID NO: 209 (NKp46-3 L1 variable domain);

(d) a VH comprising an amino acid sequence of SEQ ID NOS: 210, 211 or 212 (NKp46-4 H1 variable domain), and a VL comprising an amino acid sequence of SEQ ID NO: 213 (NKp46-4 L2 variable domain);

(e) a VH comprising an amino acid sequence of SEQ ID NO: 215 (NKp46-9 H2 variable domain), and a VL comprising an amino acid sequence of SEQ ID NOS: 217 or 218 (NKp46-9 L1 or L2 variable domain); or

(f) a VH comprising an amino acid sequence of SEQ ID NO: 216 (NKp46-9 H3 variable domain), and a VL comprising an amino acid sequence of SEQ ID NOS: 217 or 218 (NKp46-9 L1 or L2 variable domain).

2. The protein or polypeptide of claim 1 , wherein the protein is an antibody.

3. The protein or polypeptide of claim 1 , wherein the VH and the VL are placed on a single polypeptide chain and fused to one another via a peptide linker.

4. The protein or polypeptide of claim 1 , wherein the VH is positioned on a first polypeptide chain within the protein and the VL is positioned on a second polypeptide chain within the protein.

5. The protein or polypeptide of claim 2 , wherein the protein is a full length IgG antibody, or a fragment thereof that retains binding to the NKp46 polypeptides.

6. The protein or polypeptide claim 1 , wherein the protein binds a Macaca fascicularis (cynomolgus) NKp46 polypeptide.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2018
From: GAUTHIER, LAURENT; ANCERIZ, NADIA; MOREL, ARIANE; ROSSI, BENJAMIN
To: INNATE PHARMA
Reel/Frame 046315/0857 →
Continuity (2)
Provisional Application 62271474 · Dec 28, 2015
Related Publication 20180355036A1 · Dec 13, 2018
Cited By (3)
US 12,195,555 US 12,252,543 US 12,365,731